logo

FDA Calendar

Share
Company Name Vertex Pharmaceuticals Inc.
Drug Name TRIKAFTA (sNDA)
Event Name FDA decision on TRIKAFTA for the treatment of cystic fibrosis patients with additional rare CFTR mutations
Event Date 12/30/2020
Outcome Date
Outcome
Drug Status
Rival Drugs
Market Potential
Other Approvals TRIKAFTA is already approved for the treatment of cystic fibrosis in patients aged 12 years and older who have at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
News
Return to FDA Calendar